Cargando…

Lifestyle or pharmacotherapy in cardio-metabolic disease prevention

Cardio-metabolic diseases are the leading causes of premature death worldwide. The conditions are together some of the most prevalent and severe multimorbidities and include conditions such as diabetes, hypertension, coronary heart disease and stroke. People with these conditions are at a higher ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Seidu, Borenyi S., Osman, Hanad, Seidu, Samuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334018/
https://www.ncbi.nlm.nih.gov/pubmed/37381922
http://dx.doi.org/10.1177/17539447231177175
_version_ 1785070784339771392
author Seidu, Borenyi S.
Osman, Hanad
Seidu, Samuel
author_facet Seidu, Borenyi S.
Osman, Hanad
Seidu, Samuel
author_sort Seidu, Borenyi S.
collection PubMed
description Cardio-metabolic diseases are the leading causes of premature death worldwide. The conditions are together some of the most prevalent and severe multimorbidities and include conditions such as diabetes, hypertension, coronary heart disease and stroke. People with these conditions are at a higher risk of all-cause death and have a reduction in life expectancy when compared to patients without cardio-metabolic disorders. As a result of the increasing prevalence and impact of cardio-metabolic multimorbidity on disability, no healthcare system can ‘treat’ its way out of this pandemic. ‘Treating our way out’ requires the use of multiple medications which can lead to improper prescribing, insufficient compliance, overdosing or underdosing, improper drug choice, insufficient monitoring, unfavourable drug effects, and drug interactions and inappropriate wastes and costs. Therefore, individuals living with these conditions should be empowered to adopt lifestyle changes that foster independent living with their conditions. Adopting these healthy lifestyles such as smoking cessation, improving dietary habits, sleep hygiene and physical activity is a suitable adjunctive measure if not an alternative to polypharmacy in cardio-metabolic multimorbidity.
format Online
Article
Text
id pubmed-10334018
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-103340182023-07-12 Lifestyle or pharmacotherapy in cardio-metabolic disease prevention Seidu, Borenyi S. Osman, Hanad Seidu, Samuel Ther Adv Cardiovasc Dis Review Cardio-metabolic diseases are the leading causes of premature death worldwide. The conditions are together some of the most prevalent and severe multimorbidities and include conditions such as diabetes, hypertension, coronary heart disease and stroke. People with these conditions are at a higher risk of all-cause death and have a reduction in life expectancy when compared to patients without cardio-metabolic disorders. As a result of the increasing prevalence and impact of cardio-metabolic multimorbidity on disability, no healthcare system can ‘treat’ its way out of this pandemic. ‘Treating our way out’ requires the use of multiple medications which can lead to improper prescribing, insufficient compliance, overdosing or underdosing, improper drug choice, insufficient monitoring, unfavourable drug effects, and drug interactions and inappropriate wastes and costs. Therefore, individuals living with these conditions should be empowered to adopt lifestyle changes that foster independent living with their conditions. Adopting these healthy lifestyles such as smoking cessation, improving dietary habits, sleep hygiene and physical activity is a suitable adjunctive measure if not an alternative to polypharmacy in cardio-metabolic multimorbidity. SAGE Publications 2023-06-29 /pmc/articles/PMC10334018/ /pubmed/37381922 http://dx.doi.org/10.1177/17539447231177175 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Seidu, Borenyi S.
Osman, Hanad
Seidu, Samuel
Lifestyle or pharmacotherapy in cardio-metabolic disease prevention
title Lifestyle or pharmacotherapy in cardio-metabolic disease prevention
title_full Lifestyle or pharmacotherapy in cardio-metabolic disease prevention
title_fullStr Lifestyle or pharmacotherapy in cardio-metabolic disease prevention
title_full_unstemmed Lifestyle or pharmacotherapy in cardio-metabolic disease prevention
title_short Lifestyle or pharmacotherapy in cardio-metabolic disease prevention
title_sort lifestyle or pharmacotherapy in cardio-metabolic disease prevention
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334018/
https://www.ncbi.nlm.nih.gov/pubmed/37381922
http://dx.doi.org/10.1177/17539447231177175
work_keys_str_mv AT seiduborenyis lifestyleorpharmacotherapyincardiometabolicdiseaseprevention
AT osmanhanad lifestyleorpharmacotherapyincardiometabolicdiseaseprevention
AT seidusamuel lifestyleorpharmacotherapyincardiometabolicdiseaseprevention